首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >OPTIMAL AND ENSURE TRIALS - BASED COMBINED COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ASIAN PATIENTS WITH NONSQUAMOUS NON-SMALL-CELL LUNG CANCER

【24h】

OPTIMAL AND ENSURE TRIALS - BASED COMBINED COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ASIAN PATIENTS WITH NONSQUAMOUS NON-SMALL-CELL LUNG CANCER

机译：基于最优和确定性试验的厄洛替尼与化疗联合治疗非小细胞型非小细胞肺癌亚洲患者一线治疗的综合成本效益分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共2页
作者
Wen F.; Zheng H.; Zhang P.; Hutton D. W.; Li Q.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. OPTIMAL AND ENSURE TRIALS - BASED COMBINED COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ASIAN PATIENTS WITH NONSQUAMOUS NON-SMALL-CELL LUNG CANCER [J] . Wen F., Zheng H., Zhang P., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：基于最优和确定性试验的厄洛替尼与化疗联合治疗非小细胞型非小细胞肺癌亚洲患者一线治疗的综合成本效益分析
2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. [J] . Zhou C, Wu YL, Chen G, The lancet oncology . 2011,第8期

机译：厄洛替尼与化学疗法作为晚期EGFR突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL，CTONG-0802）：一项多中心，开放标签，随机，3期研究。
3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial [J] . RosellR., CarcerenyE., GervaisR., The lancet oncology . 2012,第3期

机译：厄洛替尼与标准化疗作为欧洲晚期EGFR突变阳性非小细胞肺癌（EURTAC）患者的一线治疗：一项多中心，开放标签，随机3期试验
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer [O] . Feng Wen, Hanrui Zheng, Pengfei Zhang, 2018

机译：基于OPTIMAL和ENSURE试验的厄洛替尼与化疗联合治疗亚洲非鳞状非小细胞肺癌一线患者的成本效益分析
7. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer [O] . Feng Wen, Hanrui Zheng, Pengfei Zhang, 2018

机译：欧洲非鳞状非小细胞肺癌的亚洲患者综合治疗基于试验的欧洲患者的综合性成本效果分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号